Protocol Ledger

NCT03619850 · Phase III · RECRUITING

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Interventional Phase III clinical trial protocol NCT03619850 sponsored by AMAG Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-13 Enrollment: 129 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03619850
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)129 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03619850
Protocol FieldVerified Registry Value
NCT IdentifierNCT03619850
Consolidated Lead SponsorAMAG Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment129 participants (ESTIMATED)
Registered Start Date2018-08-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03619850
Hospital Research SiteLocationSite Profile
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
West Virginia UniversityMorgantown, WVOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI